Long-term Agreements, New Launches, Acquisitions and Strategic Collaborations in Improving Medical Research - Research Report Thermo Fisher, Cubist, Agilent, Life Technologies, and Covance
NEW YORK, September 16, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts' Corner announced new research reports highlighting Thermo Fisher Scientific, Inc. (NYSE: TMO), Cubist Pharmaceuticals Inc. (NASDAQ: CBST), Agilent Technologies Inc. (NYSE: A), Life Technologies Corporation (NASDAQ: LIFE), and Covance Inc. (NYSE: CVD). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Thermo Fisher Scientific, Inc. Research Report
On September 4, 2013, Thermo Fisher Scientific Inc. (Thermo Fisher) and Siemens Healthcare Diagnostics announced the renewal of its long-term agreement for the use of Thermo Fisher's Procalcitonin (B·R·A·H·M·S PCT™) technology, available as an automated immunoassay on the Siemens ADVIA Centaur XP and CP systems in all countries outside the US and China. According to the Company, the ADVIA Centaur B·R·A·H·M·S PCT™ immunoassay offers clinicians an integrated solution for accurately diagnosing sepsis and monitoring response to antibiotic therapy, thereby helping to make improved clinical decisions. "The continuation of our close collaboration with Siemens significantly increases the global reach of this critical biomarker, making it available to a broader patient population," said Marc Tremblay, President of Thermo Fisher's Clinical Diagnostics division. The Full Research Report on Thermo Fisher Scientific, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/45ed_TMO]
--
Cubist Pharmaceuticals Inc. Research Report
On September 11, 2013, Cubist Pharmaceuticals Inc. (Cubist) announced that it has completed the acquisition of Trius Therapeutics, Inc. (Trius) for an aggregate upfront cash consideration of c.$704 million. "We are very pleased to complete this acquisition and welcome the Trius team to Cubist," said Cubist's CEO, Michael Bonney. "Trius is an excellent strategic fit, and its lead product candidate, tedizolid phosphate, has the potential to be an important new treatment in the fight against resistant infections. The need for new treatments to combat drug resistant bacteria is growing, and we will work diligently to bring this antibiotic product candidate to market in order to help hospitals and their patients combat these infections. This transaction is also an important step towards achieving Cubist's Building Blocks of Growth and continuing our track record of driving shareholder value over the long term." The Full Research Report on Cubist Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/92f2_CBST]
--
Agilent Technologies Inc. Research Report
On September 3, 2013, Agilent Technologies Inc. (Agilent) announced the launch of its 7000 C Triple Quadrupole Gas Chromatography Mass Spectrometer (GC/MS/MS). According to the Company, the improved system features new capabilities, in enhancing system performance, simplifying method optimization and lowering operating costs, and offers reliability, efficiency, and ultra-low limits of detection for ultimate confidence in trace-level analysis. Terry Sheehan, GC/MS Marketing Director at Agilent, commented, "The 7000C Triple Quadrupole GC/MS/MS, together with Agilent sample-preparation supplies, enables sensitive, selective and robust techniques for measuring trace components in complex matrices. In addition, our extensive MRM database of pesticides and environmental pollutants provides all the information needed for quick and easy method development." The Full Research Report on Agilent Technologies Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/075e_A]
--
Life Technologies Corporation Research Report
On September 10, 2013, Life Technologies Corp. (Life Technologies) announced the new Ion AmpliSeq™ Exome Certified Service Provider program, a global organization of some of the world's top service providers that will sequence and analyze human exomes in as little as two days. According to the Company, by the Ion AmpliSeq™ Exome Kit, the Ion Proton™ Sequencer, and the Ion Reporter™ Software, service providers can sequence two exomes in a single run -- from DNA to results in just two days, eliminating the need to batch samples just to make the price of exome sequencing affordable. "As a key partner with Life Technologies, the Ion AmpliSeq™ Exome Kit provides us with a workflow that is amenable to large scale variant detection for both the research and ultimately clinical research laboratories. Sequence data comparisons using a variety of enrichment and sequencing technologies confirm our commitment to delivering cost effective data for our customers using the Ion AmpliSeq™ Exome product," said Dr. Patrice Milos, CEO and President, Claritas Genomics. The Full Research Report on Life Technologies Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/d5de_LIFE]
--
Covance Inc. Research Report
On September 4, 2013, Covance Inc. (Covance) and the Indiana Clinical and Translational Sciences Institute (CTSI) jointly announced a collaboration agreement to conduct early clinical trials for new medicine on behalf of biotechnology and pharmaceutical companies. According to the Company, the partnership will conduct high-quality research in a safe and regulated environment for sponsors who are looking to recruit both healthy volunteers and patients for early clinical studies. "The alliance with the Indiana CTSI will help us provide biopharmaceutical clients with quicker access to patients in a hospital setting that supports specialized care and monitoring," said Rob Aspbury, Vice President and General Manager, Global Clinical Pharmacology Services at Covance. "With quicker access to patients, we can streamline the drug development process and bring important new medications to patients who need them." The Full Research Report on Covance Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/5691_CVD]
----
EDITOR NOTES:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by an analyst. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
- For any urgent concerns or inquiries, please contact us at [email protected].
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
AnalystsCorner.com
SOURCE Analysts' Corner
Share this article